

7. References

- Acevedo, R.; Villanueva, H.; Parnell, P. G.; Chapman, L. M.; Gimenez, T.; Gray, S. L. and Baldwin, W. S. (2005):** The contribution of hepatic steroid metabolism to serum estradiol and estriol concentrations in nonylphenol treated MMTVneu mice and its potential effects on breast cancer incidence and latency. **J. Appl. Toxicol.**, 25: 339-353.
- Ahab, N.; Kini, U.; Vinten, J.; Ayres, J.; Baker, G. and Clayton-Smith, J. (2004):** The longer term outcome of children born to mothers with epilepsy. **Neurol. Neurosurg. Psychiatry.**, 75: 1575–1583.
- Alberts, B. (1994):** Molecular Biology of the Cell. **New. York. Garland. Publishing. Inc.**, 40-48.
- Alderman, C. P. and Frith, P. A. (1999):** Fluvoxamine-methadone interaction. **Aust. N. Z. J. Psychiatry**, Feb., 33 (1): 99-101.
- Allen, E. (1922):** The oestrus cycle in the mouse. **Am. J. Anat.**, 30: 297-299.
- Altschul, S. S.; Boguski, M. S.; Gish, W. and Wootton, J. C. (1994):** Issues in searching molecular sequence. **Nature Genet.**, 6:119-129.
- Altshuler, L. L.; Cohen, L.; Szuba, M. P.; Burt, V. K.; Gitlin, M. and Mintz, J. (1996):** Pharmacological management of psychiatric illness during pregnancy, dilemmas and guidelines. **Am. J. Psychiatry.**, 153: 592-606.

- Anakk, S.; Kalsotra, A.; Kikuta, Y.; Huang, W.; Zhang, J.; Staudinger, J. L.; Moore, D. D. and Strobel, H. W. (2004):** CAR/PXR provide directives for Cyp3a41 gene regulation differently from Cyb. **Pharmac. J., 4: 91–101.**
- Anber, Gh. R. K. (2009):** Molecular riboprinting studies on the effect of tetracyclines on mice embryo. **M. Sc. Thesis, Fac. Sci., Benha Univ., 74 pp.**
- Andrew, E. C.; Brian, R. L. and Burt, V. K. (2005):** Risc and Benefit of drug use during pregnancy. **Int. J. Med. Sci., 2:100-106.**
- Autrup, H.; Harris, C. C.; Wu, S. M.; Bao, L. Y.; Pei, X. F.; Lu, S.; Sun, T. T. and Hsia, C. C. (1984):** Activation of chemical carcinogens by cultured human fetal liver, esophagus and stomach. **Chem. Biol. Interact., 50: 15–25.**
- Awwad, M.H (2003):** Molecular identification of *Biomphalaria alexandrina* and *Bulinus truncatus* using PCR –RFLP of actin gene. **J. Egypt. Acad. Soc. Environ. Develop. 3 (1): 39-52.**
- Bader , M.; Thrum, H.; Guttner, J. and Klinger, w. (1974):** Actinomycin D: toxicity, liver functions in rats. **Acta. Biol. Med. Ger., 32: 91-98.**
- Balk, E. M.; Lichtenstein, A. H.; Chung, M.; Kupelnick, B.; Chew, P. and Lau, J. (2006):** Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk. **Atherosclerosis., 189: 19-30.**

- Banhidy, F.; Brian, R. L. and Andrew, E. C. (2005):** Risk and Benefit of Drug Use during pregnancy. **Int. J. Med. Sci., 2: 100-106.**
- Bartle, W. R.; Walker, S. E. and Shapero, T. (1983):** Dose-dependent effect of cimetidine on phenytoin kinetics. **Clin. Pharmacol. Ther., 33: 649-655.**
- Bar-Oz, B.; Nulman, I.; Koren, G. and Ito, S. (2000):** Anticonvulsants and breast feeding: a critical review. **Paediatr. Drugs., 2: 113-126.**
- Behrman, R. E. (1996):** Textbook of Pediatrics. 15thed. Philadelphia: WB. Saunders, 448-451.
- Berkow, R. (1992):** The Merck Manual of Diagnosis and Therapy. 16th ed. Rahway, NJ: Merck Research Laboratories. 1857-1862.
- Binder, L.; Trujillo, J.; Parker, D. and Cuetter, A. (1996):** Association of intravenous phenytoin toxicity with demographic, clinical and dosing parameters. **Am. J. Emergency. Med., 14: 398-401.**
- Booker, B. Schulte, U. and Weiss, H. (2001):** Lack of effect of methadone (MET) on the pharmacokinetics (PK) of delavirdine (DLV) and N-delavirdine (N-DLV). 41st. Interscience Conference on Antimicrobial Agents and Chemotherapy. December., 16-19: Chicago. Illinois., 490.
- Borlakoglu, J. T.; Edwards-Webb, J. D. and Dils, R. R.(1991):** Evidence for the induction of fatty acids proliferating hepatic endoplasmic reticulum. **Int. J. Biochem., 23:925-929.**

- Camble, K.; Sharova, L. V.; Ward, D. L.; Holladay, S. D. and Neil, E. (2006):** Biology: concepts and connections. San Francisco: Benjamin. Cummings. I. S. B. N., 0-8053: 7160-7165.
- Chaiken, B. H.; Goldberg, B. I. and Segal, J. P. (1950):** Dilantin sensitivity. Report of a case of hepatitis with jaundice, pyrexia, and exfoliative dermatitis. *N. Engl. J. Med.*, **242**: 897-898.
- Cheng, S.; Fockler, C.; Barnes, W. M. and Higuchi, R. (1994):** Effective amplification of long targets from cloned inserts and human genomic DNA. *Proc. Natl. Acad. Sci.*, **91**: 5695-5699.
- Chien-Chun, N.; Bellantuono, C.; Migliarese, G. and Gentile, S. (2007):** Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic review. *Hum. Psychopharmacol.* Apr., **22** (3): 121-128.
- Chisholm, C. A. and Kuller, J. A. (1997):** A guide to the safety of CNS-active agents during breastfeeding. *Drug Saf.*, **17**: 127-142.
- Cramer, J. A.; Mattson, R. H.; Bennett, D. M. and Swick, C. T. (1986):** Variable free and total valproic acid concentrations in sole- and multi-drug therapy. *Ther. Drug. Monit.*, **8** (4): 411-415.
- Crawford, P. (2002):** Interactions between antiepileptic drugs and hormonal contraception. *C. N. S. Drugs.*, **16**: 263-272.
- Crofts, A. R. (2004):** The cytochrome bc1 complex: function in the context of structure. *Annu. Rev. Physiol.*, **66**: 689-733.

- Crofts, A. R. and Berry, E. A. (1998):** Structure and function of the cytochrome bc₁ complex of mitochondria and photosynthetic bacteria. **Curr. Opin. Struct. Biol.**, **8**: 501-509.
- Cullen, G.(2007):** Constipation and pregnancy. **Best. Pract. Res. Clin. Gastroenterol.**, **21(5)**: 807-818.
- Cuskelly, W. O.; Hernandez-Diaz, S.; Arbogast, P. G.; Dudley, J. A.; Dyer, S. and Gideon, P. S. (2007):** Major congenital malformations after first-trimester exposure to ACE inhibitors. **N. Engl. J. Med. Jun.**, **8**. 354 (23): 2443-2451.
- Czeizel, A. E. (1999):** Ten years of experience in periconceptional care. **Eur. J. Obstet. Gynec. Reprod. Biol.**, **84**: 43-49.
- Degli Esposti, M.; Vries, S.; Crimi, M.; Ghelli, A.; Patarnello, T. and Meyer, A. (1993):** Mitochondrial cytochrome-*b*—evolution and structure of the protein. **Biochim. Biophys. Acta.**, **1143**: 243–271.
- DiPiro, J. T.; Talbert, R. L.; Yee, G. C.; Matzke, G. R.; Wells, B. G. and Posey, L. M. (1997):** Pharmacotherapy: A Pathophysiologic Approach. 3rd. ed. Stamford. C. T. Appleton & Lange., 1565-1584.
- Drory, V. E. and Korczyn, A. D. (1993):** Hypersensitivity vasculitis and systemic lupus erythematosus induced by anticonvulsants. **Clin. Neuropharmacol.**, **16**: 19-29.
- Duerksen-Hughes, P. J.; Yang, J. and Ozcan, O. (1999):** *p53* induction as a genotoxic test for twenty-five chemicals undergoing in vivo carcinogenicity testing. **Environ. Health. Perspect.**, **107**: 805–812.

- Duncan, S. (2001):** Polycystic ovarian syndrome in women with epilepsy. **A review. Epilepsia., 42 (suppl 3): 60–65.**
- Edmunds, M. W. and Mayhew, M. S. (2000):** Pharmacology for the Primary Care Provider. **Baltimore. M. d. Mosby., 115.**
- Fabro, S. and Scialli, A. R. (1986):** Drug and chemical action in pregnancy. **Marcel. Dekker., 434-437.**
- Finn, C. A. and McLaren, A. (1967):** A study of the early stages of implantation in mice. **J. Repord. Fertil. 13: 259-267.**
- Francis, J. and Burnham, M. (1992):** Phenytoin identifies a novel anticonvulsive-binding domain on voltage-dependent sodium channels. **Mol. Pharmacol., 42: 1097-1103.**
- Frederiksen, M. C.; Ruo, T. I.; Chow, M. J. and Atkinson, A. J. (1986):** Theophylline pharmacokinetics in pregnancy. **Clin. Pharmacol. Ther., 40: 321–328.**
- Gachon , F.; Fabienne, F. O.; Olivier, S.; Patrick, D. and Ueli, S. (2004):** Department of molecular biology , national center of competence in research; frontiers in genetics. **Cell Metabolism., 25-36.**
- Ghosal, A.; Sadrieh, N.; Reik, L.; Levin, W. and Thomas, P. E. (1996):** Induction of the male-specificcytochrome P450 3A2 in female rats by phenytoin. **Arch. Biochem. Biophys., 332: 153-162.**

- Guengerich, F. P. (1994):** Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity. **Toxicol. Lett., 70: 133-138.**
- Harris, J. W.; Rahman, A.; Kim, B. R.; Guengerich, F. P. and Collins, J. M. (1994):** Metabolism of taxol by human hepatic microsomes and liver slices. participation of cytochrome P450 3A4 and an unknown P450 enzyme. **Cancer Res., 54: 4026-4035.**
- Heilig, E. and Egli, G. L. (2006):** Prenatal exposure to antiepileptic drugs. **Lancet May., 367(9521): 1467-1469.**
- Henze, K. and Martin, W. (2003):** Evolutionary biology. Essence of mitochondria. **Nat., 426: 127-128.**
- Hines, R. N. and Mc Carver, D. G. (2002):** The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. **J. Pharmacol. Exp. Ther., 300: 355-360.**
- Holmes, L. B.; Harvey, E. A.; Coull, B. A.; Huntington, B. A.; Khoshbin, S. and Hayes, A. M. (2001):** The teratogenicity of anticonvulsant drugs. **N. Engl. J. Med., 344: 1132–1138.**
- Hunt, S. J. (1995):** Cutaneous necrosis and multinucleate epidermal cells associated with intravenous phenytoin. **Am. J. Dermatopathol., 17: 399-402.**
- Huyck, Z. and Ann, M. (1999):** Tackling Therapeutic Challenges in Pregnant and Breast-Feeding Patients. **Pharmacy. Times., 65. 8: 118-127.**

- Iwata, S.; Lee, J.W.; Okada, K.; Lee, J.K.; Iwata, M.; Rasmussen, B.; Link, T.A.; Ramaswamy, S. and Jap, B.K. (1998):** Complete structure of the 11subunit bovine mitochondrial cytochrome bc₁ complex. **Science.**, **281**: 64-71.
- Joseph, S. A. B. and David, W. (2001):** Molecular Cloning. Chapter 8: In vitro Amplification of DNA by the Polymerase Chain Reaction. **A Laboratory Manual, 3rd ed., Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory. Press. I. S. B. N., 87969: 576-585.**
- Juchau, M. R. (1985):** Biotransformations of drugs and foreign chemicals in the human fetal-placental unit. **NIDA. Res. Monogr.**, **60**: 17-24.
- Juchau, M. R.; Fantel, A. G.; Harris, C. and Beyer, B. K. (1986):** The potential role of redox cycling as a mechanism for chemical teratogenesis. **Environ. Health. Perspect.**, **70**: 131–136.
- Kajekar, R. (2007):** Environmental factors and developmental outcomes in the lung. **Pharma. & Therap.**, **114**: 129-145.
- Kaminsky, L. S. and Zhang, Z. Y (1997):** Human P450 metabolism of warfarin. **Pharma. Therap.**, **73**: 67-74.
- Kaur, S.; Goraya, J. S.; Thami, G. P. and Kanwar, A. J. (2002):** Pellagrous dermatitis induced by phenytoin. **Pediatr. Dermatol.**, **19**: 93.
- Kobayashi, K.; Iijima, M.; Ushikai, M.; Ikeda, S. and Saheki, T. (2007):** Citrin deficiency. **J. Jpn. Pediatr. Soc.**, **110**: 1047–1059.

- Koren, G.; Pastusnak, A. and Ito, S. (1998):** Drugs in pregnancy. *N. Engl. J. Med.*, 338: 1128-1137.
- Kramer, D. M.; Roberts, A. G.; Muller, F.; Cape, J. and Bowman, M. K. (2004):** Q.cycle bypass reactions at the Qo site of the cytochrome bc1 (and related) complexes. *Methods. Enzymol.*, 382: 21-45.
- Lee, K. W. and Lip, G. Y. H.(2003):** The role of omega-3 fatty acids in the secondary prevention of cardiovascular disease. *Q. J. Med.*, 96: 465-480.
- Levy, R. H. (1995):** Cytochrome B isozymes and antiepileptic drug interactions. *Epilepsia.*, 36 (Suppl 5): S., 8-13.
- Lewis, D. P.; Van Dyke, D. C.; Willhite, L. A.; Stumbo, P. J. and Berg, M. J. (1995):** Phenytoin-folic acid interaction. *Ann. Pharmacother.* Jul. Aug., 29(7-8): 726-735.
- Li, R.; Ciblack, M. A. and Nordoff, N. (2000):** In vitro activities of voriconazole, itraconazole and amphotericin B against *Blastomyces dermatitidis*, *Coccidioides immitis*, and *Histoplasma capsulatum*. *Antimicrobial Agents. and Chemotherapy.*, 44(6): 1734-1736.
- Lin, J. H. and Lu, A. Y. (1997):** Role of pharmacokinetics and metabolism in drug discovery and development. *Pharmacol. Rev.*, 49: 403-449.
- Mahadevan, U. (2007):** Gastrointestinal medications in pregnancy. *Best. Pract. Res. Clin. Gastroenterol.*, 21(5): 849-877.

- Manto, M.; Preiser, J. C. and Vincent, J. L. (1996):** Hypoglycemia associated with phenytoin intoxication. **Clin. Toxicol.**, 34: 205-208.
- Margaretten, N. C.; Hincks, J. R.; Warren, R. P.; Coulombe, R. A. (1987):** Effects of phenytoin and carbamazepine on human natural killer cell activity and genotoxicity in vitro. **Toxicol. Appl. Pharmacol.**, 87: 10-17.
- Masuyama, H.; Hiramatsu, Y. M. K.; Takafumi, K. and MacDonald, P. N. (2000):** Endocrine disrupting chemicals, phthalic acid and nonylphenol, activate pregnane X receptor-mediated transcription. **Mol. Endocrinol.**, 14: 421–428.
- Mather, M. W., Yu, L. and Yu, C. A. (1995):** **J. Biol. Chem.**, 270: 28668-28675.
- Mcpherson, S. J.; Wang, H.; Jones, M. E.; Pedersen, J.; Iismaa, T. P.; Wreford, N.; Simpson, E. R. and Risbridger, G. P. (2001):** Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland. **Endocrinology**, 142: 2458–2467.
- Mirkes, P. E.; Little, S. A. and Shield, M. A. (1997):** The bcl-2 gene family. Apoptosis and developmental toxicology. **Toxicology**, 36-42.
- Mock, D. M. ; Mock, N. I. ; Nelson, R. P. and Lombard, K.A. (1998):** Disturbances in biotin metabolism in children undergoing long-term anticonvulsant therapy. **J. Pediatr. Gastroenterol. Nutr.**, 26: 245-250.

- Moffatt, D. C. and Bernstein, C. N. (2007):** Drug therapy for inflammatory bowel disease in pregnancy and the puerperium. **Best. Pract. Res. Clin. Gastroenterol.**, 21(5): 835-847.
- Moore, K. L. and Persaud, T. V. N. (1998):** The Developing Human: Clinically oriented embryology. **W. B. Saunders. Co., 6th. Ed.**
- Mullis, K. B. (1990):** The unusual origin of the polymerase chain reaction. **Sci. Am.**,262(4): 56-61.
- Murray, M. and Reidy, G. F. (1990):** Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. **Pharmacol. Rev.**, 42: 85-101.
- Nanda, A.; Kaur, S.; Bhakoo, O. N.; Kapoor, M. M. and Kanwar, A. J. (1989):** Fetal hydantoin syndrome: a case report. **Pediatr. Dermatol.**, 6: 130-133.
- Nelson, D. R.; Kamataki, T.; Waxman, D. J.; Guengerich, F. P.; Estabrook, R. W. and Feyereisen, R. (1993):** The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. **DNA. Cell. Biol.**, 12: 1-51.
- Nonacs, R. and Cohen, L. S. (2003):** Assessment and treatment of depression during pregnancy: an update. **Psychiatr. Clin. North. Am.**, 26(3): 547–562.

- Ochoa, A.; Garbis, H.; Elefant, E.; Diav-Citrin, O.; Mastroiacovo, P. (2005):** Pregnancy outcome after exposure to phenytoin and other H2-blockers. A collaborative study of the European. **Network. of. Teratology. Information. Services. Reprod. Toxicol., 19: 453-458.**
- Okada, K.; Sugiura, T.; Kuroda, E.; Tsuji, S. and Yamashita, U. (2001):** Phenytoin promotes Th2 type immune response in mice. **Clin. Exp. Immunol., 124: 406-413.**
- Okamoto, Y.; Shimizu, K.; Tamura, K.; Yamada, M.; Matsui, Y.; Hayakawa, T. and Mogami, H. (1989):** Effects of anticonvulsants on cellular immunity. **Shinkei., 41: 299-304.**
- Oltvai, Z. N.; Milliman, C. L. and Korsmeyer, S. J. (1993):** BCL-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. **Cell, 74: 609–619.**
- Pavlov, A. R.; Pavlova, N. V.; Kozyavkin, S. A. and Slesarev, A. I. (2004):** Recent developments in the optimization of thermostable DNA polymerases for efficient applications. **Trends. Biotechnol., 22: 253-260.**
- Pavlov, A. R.; Pavlova, N. V.; Kozyavkin, S. A. and Slesarev, A. I. (2006):** Thermostable DNA Polymerases for a Wide Spectrum of Applications: Comparison of a Robust Hybrid TopoTaq to other enzymes, in Kieleczawa. **J. DNA Sequencing II: Optimizing Preparation and Cleanup. Jones and Bartlett. pp., 241-257. I. S. B. N., 7637338-7637343.**

- Pennell, P. B. (2003):** Antiepileptic drug pharmacokinetics during pregnancy and lactation. **Neurol.**, **61**: S., 35-42.
- Perea, S.; Fothergill, A. W. and Sutton, D. (2001):** Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method. **J. Clin. Microbiol.**, **39**(1): 385-388.
- Putignano, P.; Kaltsas, G. A.; Satta, M. A. and Grossman, A. B. (1998):** The effects of anti-convulsant drugs on adrenal function. **Horm. Metab. Res.**, **30**: 389-397.
- Rabinow, A. C. and Paul, S. (1996):** Making PCR: A Story of Biotechnology. Chicago: University of Chicago Press. **I. S. B. N.**, **0-226: 70146-70148**.
- Ram, J. L.; Ram, M. L. and Baidoum, F. F. (1996):** Authentication of canned tuna and bonito by sequence and restriction site analysis of polymerase chain reaction (PCR) products of mitochondrial DNA (mtDNA). **J. Agric. Food. chem.**, **44**: 2460-2467
- Robson, S. C.; Mutch, E.; Boys, R. J. and Woodhouse, K. W. (1990):** Apparent liver blood flow during pregnancy: a serial study using indocyanine green clearance. **Brit. J. Obstet. Gynaecol.**, **97**: 720–724.
- Ross, S.; Ormerod, A. D. and Roberts, C. (2002):** Subacute cutaneous lupus erythematosus associated with phenytoin. **Clin. Exp. Dermatol.**, **27**: 474-476.
- Scheffler, I. E. (2001):** A century of mitochondrial research: achievements and perspectives. **Mitochondrion.**, **1** (1): 3-31.

- Schuetz, J. D.; Beach, D. L. and Guzelian, P. S. (1994):** Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. **Pharmacogenetics, 4: 11-20.**
- Silverman, A. K.; Fairley, J. and Wong, R. C. (1988):** Cutaneous and immunologic reactions to phenytoin. **J. Am. Acad. Dermatol., 18: 721-741.**
- Slaughter, R. L. and Edwards, D. J. (1995):** Recent advances: the cytochrome P450 enzymes. **Ann. Pharmacother., 29: 619-624.**
- Sonoda, J. and Evans, R. M. (2003):** Biological function and mode of action of nuclear xenobiotic receptors. **Pure. Appl. Chem., 75:1733–1742.**
- Speight, T. M. and Holford, N. H. G. (1997):** Avery's Drug Treatment. 4th. ed. Auckland. New Zealand. Adis. International Limited., 76-126: 684-698.
- Steffensen, R.; Thiel, S.; Varming, K.; Jersild, C. and Jensenius, J. C. (2000):** Detection of structural gene mutation and promoter polymorphisms in the mannan- binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. **J. Immunol. Meth., 241: 33-42.**
- Stroebel, D.; Choquet, Y.; Popot, J. L. and Picot, D. (2003):** An atypical haem in the cytochrome b(6)f complex. **Nature, 426: 413-418.**
- Tarusao, D. (2002):** Folic acid: from research to public health practice. Report of W. H. O. Regional Office for Europe and the Instituto Superiore di Sanita., 11-12.

- Terada, M. and Nishimura, H. (1975):** Mitigation of caffeine – induced teratogenicity in mice by prior chronic caffeine ingestion. *Teratology*, 12: 79 – 82.
- Tsutsumi, K.; Kotegawa, T.; Matsuki, S.; Tanaka, Y.; Ishii, Y. and Kodama, Y. (2001):** The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans. *Clin. Pharmacol. Ther.*, 70:121–125.
- Tuchmann – Duplessis, H. (1970):** Influence of certain drugs on the prenatal development. *Int. J. Gynecol. Obstet.*, 8: 777- 792.
- Vallance, P. (1996):** Drugs and the fetus. *Brit. Med. J.*; 312: 1053 - 1054.
- Verdeguer, J. M.; Ramon, D.; Moragon, M.; Betlloch, I.; Jorda, E. and Planelles, M. V. (1988):** Onychopathy in a patient with fetal hydantoin syndrome. *Pediatr. Dermatol.*, 5: 56-57.
- Von Schacky, R. and Harris, W. S. (2007):** Cardiovascular benefits of omega-3 fatty acids. *Cardiovasc. Res.*, 73: 310-315.
- Wells, P. G., Kim, P. M., Laposa, R. R., Nicol, C. J., Parman, T., and Winn, L. M. (1997):** Oxidative damage in chemical teratogenesis. *Mutat. Res.*, 396: 65–78.
- Wells, P. G. and Winn, L. M. (1996):** Biochemical toxicology of chemical teratogenesis. *Crit. Rev. Biochem. Mol. Biol.*, 31: 1–40.
- Wiwi, C. A.; Gupte, M.; Waxman, D. J. (2004):** Sexually dimorphic P450 gene expression in liver-specific hepatocyte nuclear factor 4a-deficient mice. *Mol. Endocrinol.*, 18: 1975–1987.

- Wyszynski, D.; Nambisan, M.; Surve, T.; Alsdorf, R. M.; Smith, C. and Holmes, L. B. (2005):** Increased risk of major malformations in offspring exposed to valproate during pregnancy. **Neurology**, **64**: 961–965.
- Yamada, H.; Gohyama, N.; Honda, S.; Hara, T.; Harada, N. and Oguri, K. (2002):** Estrogen dependent regulation of the expression of hepatic Cyp2b and 3a isoforms: assessment using aromatase-deficient mice. **Toxicol. Appl. Pharmacol.**, **180**: 1–10.
- Yerby, M. S.; Friel, P. N. and McCormick, K. (1992):** Antiepileptic drug disposition during pregnancy. **Neurology**, **42 (suppl 5)**: 12-16.
- Young, L. Y. and Koda-Kimble, M. A. (1995):** Applied Therapeutics: The Clinical Use of Drugs. **6th. ed. Vancouver. W. A. Applied. Therapeutics Inc.**, **45**: 2-3.
- Zhang, Q. Y.; Dunbar, D. and Kaminsky, L.S. (2003):** Characterization of mouse small intestinal cytochrome P450 expression. **Drug. Metab. Dispos.**, **31**: 1346–1351.
- Zhang, Z.; Huang, L.; Shulmeister, V. M.; Chi, Y. I.; Kim, K. K. and Hung, L. W.; Crofts, A. R.; Berry, E. A. and Kim, S. H. (2001):** Electron transfer by domain movement in cytochrome bc1. **Nature**, **392**: 677-684.